Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Development by Year
Development — Outsourced services ex-drug supply (FY2013–FY2018, $M) ($M)
Vertex Pharmaceuticals Development: $344M in FY2018, up 1.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2018 figure comes from
“|| Outsourced services | 344,339 | 337,901 | 282,137 | 6,438 | 2 | % | 55,764 | 20 | %”
Source: Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
Reported in Form 10-Q / 10-K MD&A (Development Expenses Disaggregation Table).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development — Outsourced services ex-drug supply (FY2013–FY2018, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 344 | +1.9% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 338 | +19.8% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 282 | +13.5% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 249 | +25.7% | Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗ |
| FY2014 | Dec 31, 2014 | 198 | -17.2% | Form 10-K (a201610k-main.htm, filed 2017-02-23) ↗ |
| FY2013 | Dec 31, 2013 | 239 | – | Form 10-K (a201510k-main.htm, filed 2016-02-16) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Development ($M), annual FY2013–FY2018 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-outsourced-pure
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.